Eledon Pharmaceuticals, Inc. 8-K

What Happened Eledon Pharmaceuticals, Inc. announced that its stockholders approved an amendment to the company’s Certificate of Incorporation at the Annual Meeting held June 18, 2026. The Company filed a Certificate of Amendment with the Delaware Secretary of State, effective June 22, 2026, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000. The Certificate of Amendment is included as Exhibit 3.1 to the Form 8-K.

Key Details

• Authorized common shares increased from 300,000,000 to 450,000,000 (an increase of 150,000,000 shares).
• Stockholder approval occurred at the Annual Meeting on June 18, 2026.
• Certificate of Amendment filed with the Delaware Secretary of State and effective June 22, 2026; Exhibit 3.1 attached to the 8-K.
• Form 8-K signed by CEO David‑Alexandre C. Gros, M.D., dated June 22, 2026.

Why It Matters Increasing authorized shares gives Eledon flexibility to issue additional common stock in the future for purposes such as raising capital, equity compensation, or potential acquisitions. The amendment itself does not issue new shares or change outstanding share count—any future issuances would be disclosed in subsequent filings and could dilute existing shareholders if and when shares are issued. Investors should watch for follow-on filings (e.g., registration statements, prospectuses, or equity grants) that would indicate how and when the new authorization will be used.